ChiCTR2600126893 版本V1.0 版本创建时间2026/06/18 11:47:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126893 

最近更新日期:

Date of Last Refreshed on:

2026-06-18 11:46:59 

注册时间:

Date of Registration:

2026-06-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

星诺瞳?双效离焦软镜用于儿童青少年视力矫正和近视防控的有效性、安全性、适应性研究

Public title:

Research on the Efficacy, Safety, and Adaptability of Star Diffusion? Dual-Effect Defocus Soft Contact Lenses for Visual Correction and Myopia Control in Children and Adolescents

注册题目简写:

English Acronym:

研究课题的正式科学名称:

星诺瞳?双效离焦软镜用于儿童青少年视力矫正和近视防控的有效性、安全性、适应性研究

Scientific title:

Research on the Efficacy, Safety, and Adaptability of Star Diffusion? Dual-Effect Defocus Soft Contact Lenses for Visual Correction and Myopia Control in Children and Adolescents

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

余继锋 

研究负责人:

余继锋 

Applicant:

Yu Jifeng 

Study leader:

Yu Jifeng 

申请注册联系人电话:

Applicant telephone:

+86 10 5961 2345

研究负责人电话:

Study leader's
telephone:

+86 10 5961 2345

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jeffernyu@126.com

研究负责人电子邮件:

Study leader's E-mail:

jeffernyu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区南礼士路56号

研究负责人通讯地址:

北京市西城区南礼士路56号

Applicant address:

No. 56, Nanlishi Road, Xicheng District, Beijing

Study leader's address:

No. 56, Nanlishi Road, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京儿童医院

Applicant's institution:

Beijing Children‘s Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京儿童医院

Affiliation of the Leader:

Beijing Childrens Hospital,Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2026]-Y-117-D

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京儿童医院医学伦理委员会(B组)

Name of the ethic committee:

Medical Ethics Committee of Beijing Children's Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-06-05 00:00:00

伦理委员会联系人:

张怡

Contact Name of the ethic committee:

Zhang Yi

伦理委员会联系地址:

北京市西城区南礼士路56号

Contact Address of the ethic committee:

No. 56, Nanlishi Road, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 58531216

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zyhoney819@163.com

研究实施负责(组长)单位:

首都医科大学附属北京儿童医院

Primary sponsor:

Beijing Childrens Hospital,Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区南礼士路56号

Primary sponsor's address:

No. 56, Nanlishi Road, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京儿童医院

具体地址:

北京市西城区南礼士路56号

Institution
hospital:

Beijing Childrens Hospital,Capital Medical University

Address:

No. 56, Nanlishi Road, Xicheng District, Beijing

经费或物资来源:

爱博诺德(北京)医疗科技股份有限公司

Source(s) of funding:

Eyebright Medical Technology (Beijing) Co., Ltd.

研究疾病:

近视  

Target disease:

Myopia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

与普诺瞳?角膜塑形用硬性透气接触镜相比,评价星诺瞳?双效离焦软镜用于儿童青少年近视患者矫正视力和近视防控的有效性、安全性和适应性。  

Objectives of Study:

To evaluate the efficacy, safety, and adaptability of Star Diffusion? dual-effect defocus soft contact lenses compared with iBright? rigid gas permeable contact lenses for orthokeratology in visual correction and myopia control in pediatric and adolescent patients with myopia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄在8~16岁,男女不限;
2.散瞳主观验光后,双眼等效球镜度在-1.00 D~-6.00 D之间(包含-1.00D和-6.00D);散光度数≤1.50 D,屈光参差≤1.00 D;
3.框架眼镜单眼最佳矫正视力0.0 LogMAR或更好;隐形眼镜单眼最佳矫正视力0.1 LogMAR或更好;
4.角膜曲度在40.00D~46.00D之间;
5.在研究期间,能够遵循眼镜配戴要求,若中断需通知研究者;
6.患者及监护人愿意完成访视并签署知情同意书。

Inclusion criteria

1. Age between 8 and 16 years, male or female; 2. After cycloplegic subjective refraction, spherical equivalent refraction of both eyes between -1.00 D and -6.00 D (inclusive); cylinder power <=1.50 D; anisometropia <= 1.00 D. 3. Best corrected visual acuity with spectacles of 0.0 LogMAR or better in each eye; best corrected visual acuity with contact lenses of 0.1 LogMAR or better in each eye. 4. Corneal curvature between 40.00 D and 46.00 D; 5. Able to comply with the contact lens wearing requirements during the study period, and to notify the investigator if discontinuation is necessary. 6. Patients and their guardians are willing to complete follow-up visits and sign the informed consent form.

排除标准:

1. 早产儿(早于30周或<1500 g);
2. 近1个月内使用过或者正在使用延缓近视进展的产品,如特殊设计的近视控制镜(包括框架眼镜、OK镜、RGP、多焦接触镜、渐进多焦镜片等)、阿托品类药物,经研究者判断会影响试验结果;
3. 研究参与者似乎表现出不良的个人卫生情况,经研究者判断不能配戴;
4. 可能会影响视觉功能或屈光发育的眼部和全身异常,经研究者判断不能配戴;
5. 有眼内手术史者;
6. 有配戴接触镜的禁忌症;
7. 显性斜视或双眼视觉异常;
8. 已知对荧光素、奥布卡因、丙美卡因、托吡卡胺或接触镜护理产品过敏;
9. 使用任何干扰角膜接触镜配戴、泪膜产生、瞳孔大小、调节性、屈光状态或需要在配戴时间取出镜片的全身或局部眼用药物或者非处方人工泪液;
10. 圆锥角膜或不规则角膜;
11. 有角膜知觉减退、角膜溃疡、角膜浸润、眼部病毒或真菌感染,或其他复发性眼部感染的病史;
12. 存在其他经研究者判断不可配戴的情况。

Exclusion criteria:

1. Premature infants (born before 30 weeks of gestation or with birth weight < 1500 g).
2. Use of any myopia control products (e.g., specially designed myopia control spectacles including frame lenses, orthokeratology lenses, rigid gas permeable contact lenses, multifocal contact lenses, progressive addition lenses; or atropine-like medications) within the past 1 month, or ongoing use at the time of enrollment, which in the investigator's judgment may affect the study results.
3. Participants who appear to have poor personal hygiene that, in the investigator's judgment, would preclude contact lens wear.
4. Presence of ocular or systemic abnormalities that may affect visual function or refractive development and that, in the investigator's judgment, would preclude contact lens wear.
5. History of intraocular surgery.
6. Presence of any contraindication to contact lens wear.
7. Manifest strabismus or binocular vision abnormality.
8. Known allergy to fluorescein, oxybuprocaine, proparacaine, tropicamide, or contact lens care products.
9. Use of any systemic or topical ophthalmic medications, or over-the-counter artificial tears, that may interfere with contact lens wear, tear film production, pupil size, accommodation, refractive status, or require lens removal during wear.
10. Keratoconus or irregular cornea.
11. History of decreased corneal sensitivity, corneal ulcer, corneal infiltration, ocular viral or fungal infection, or other recurrent ocular infections.
12. Any other conditions that, in the investigator's judgment, would preclude contact lens wear.

研究实施时间:

Study execute time:

From 2026-06-12 00:00:00 To 2028-02-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-07-31 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

70

Group:

Control group

Sample size:

干预措施:

配戴普诺瞳?角膜塑形用硬性透气接触镜

干预措施代码:

Intervention:

Wearing iBright?Rigid Gas Permeable Contact Lens for Orthokeratology

Intervention code:

组别:

试验组

样本量:

70

Group:

Experimental group

Sample size:

干预措施:

配戴星诺瞳?双效离焦软镜

干预措施代码:

Intervention:

Wearing Star Diffusion? Dual-Effect Defocus Soft Contact Lenses

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Childrens Hospital,Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

内蒙古自治区 

市(区县):

 

Country:

China

Province:

Inner Mongolia Autonomous Region

City:

单位(医院):

内蒙古医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Inner Mongolia Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西省 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安市人民医院(西安市第四医院) 

单位级别:

三级甲等 

Institution
hospital:

Xi’an People’s Hospital (Xi’an Fourth Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脉络膜厚度

指标类型:

次要指标

Outcome:

Choroidal thickness

Type:

Secondary indicator

测量时间点:

戴镜1个月、6个月和12个月

测量方法:

Measure time point of outcome:

At 1 month, 6 months, and 12 months of wearing lenses

Measure method:

指标中文名:

视力

指标类型:

次要指标

Outcome:

Visual acuity

Type:

Secondary indicator

测量时间点:

戴镜后1周、1个月、3个月、6个月、9个月、12个月

测量方法:

Measure time point of outcome:

At 1 week, 1 month, 3 months, 6 months, 9 months and 12 months of wearing lenses

Measure method:

指标中文名:

眼轴长度

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

戴镜12个月

测量方法:

Measure time point of outcome:

At 12 months of wearing lenses

Measure method:

指标中文名:

视觉质量

指标类型:

次要指标

Outcome:

Visual quality

Type:

Secondary indicator

测量时间点:

戴镜1周,1个月,3个月,6个月,9个月和12个月

测量方法:

Measure time point of outcome:

At 1 week, 1 month, 3 months, 6 months, 9 months and 12 months of wearing lenses

Measure method:

指标中文名:

裂隙灯

指标类型:

次要指标

Outcome:

Slit lamp

Type:

Secondary indicator

测量时间点:

戴镜1周,1个月,3个月,6个月,9个月和12个月

测量方法:

Measure time point of outcome:

At 1 week, 1 month, 3 months, 6 months, 9 months and 12 months of wearing lenses

Measure method:

指标中文名:

眼轴长度

指标类型:

次要指标

Outcome:

Axial length

Type:

Secondary indicator

测量时间点:

戴镜后1个月、3个月、6个月、9个月

测量方法:

Measure time point of outcome:

At 1 month, 3 months, 6 months and 9 months of wearing lenses

Measure method:

指标中文名:

屈光度

指标类型:

次要指标

Outcome:

Refraction

Type:

Secondary indicator

测量时间点:

戴镜1个月、3个月、6个月、9个月、12个月

测量方法:

Measure time point of outcome:

At 1 month, 3 months, 6 months, 9 months and 12 months of wearing lenses

Measure method:

指标中文名:

角膜内皮

指标类型:

次要指标

Outcome:

Corneal endothelium

Type:

Secondary indicator

测量时间点:

戴镜后6个月和12个月

测量方法:

Measure time point of outcome:

At 6 months and 12 months of wearing lenses

Measure method:

指标中文名:

眼压

指标类型:

次要指标

Outcome:

Intraocular pressure

Type:

Secondary indicator

测量时间点:

戴镜6个月和12个月

测量方法:

Measure time point of outcome:

At 6 months and 12 months of wearing lenses

Measure method:

指标中文名:

泪膜评估

指标类型:

次要指标

Outcome:

Tear Film Evaluation

Type:

Secondary indicator

测量时间点:

戴镜1个月、3个月、6个月和12个月

测量方法:

Measure time point of outcome:

At 1 month, 3 months, 6 months and 12 months of wearing lenses

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 16 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-18 11:46:59